Patients with higher WAKMAR2 expression had significantly longer overall survival than the patients whose WAKMAR2 expression was lower, such as in breast invasive carcinoma (BRCA), pancreatic adenocarcinoma (PAAD), Pheochromocytoma/paraganglioma (PCPG), stomach adenocarcinoma (STAD), and thyoma (THYM) (Fig. 8a–h). Here, WAKMAR2 is linked to pheochromocytoma-paraganglioma.